ネオアジュヴァントセミプリマブによる皮膚状細胞がん治療の有効性に関する系統的レビュー
Maria Eduarda Palomba1, Julia Adriana Karmirski2, Flávio Carneiro Hojaij2
1Faculdade de Ciências Médicas da Santa Casa de São Paulo, FCMSCSP, Sao Paulo 01224-001, SP, Brazil.
International journal of molecular sciences
|August 28, 2025
まとめ
ネオアドジュバントのセミプリマブは,皮膚状細胞癌 (cSCC) の治療に高い有効性を示し,改善された応答率と管理可能な副作用をもたらしました. この免疫療法のアプローチは 進行した皮膚がんの伝統的な治療法に 期待できる選択肢です
科学分野:
- 腫瘍学
- 免疫療法
- 皮膚科
背景:
- 皮膚状細胞癌 (cSCC) は,しばしば手術または化学療法で治療される一般的な皮膚癌であり,変形および機能的欠損を引き起こす可能性があります.
- 新興の免疫療法の戦略は,特にネオアジュバントの設定では,高度なcSCCに希望を示しています.
- 進行性cSCCでは有効性が実証されており,ネオアジュバント療法として検討されています.
研究 の 目的:
- 皮膚状細胞癌 (cSCC) の新補助療法としてのセミプリマブの有効性と安全性を評価する.
- cSCC患者における新補助剤セミプリマブの反応率,有害事象,および総合的な治療可能性を分析する.
主な方法:
- PRISMAのガイドラインに従って,新補助剤セミプリマブに関する研究を分析した.
- 検索したデータベースには,PubMed,Web of Science,Scopusが含まれており,制御試験,コホート研究,ケースシリーズ,および体系的なレビューが含まれています.
- 6件の臨床試験から得られた有効性および安全性に関する重要なデータを分析した.
主要な成果:
- ネオアジュバントのセミプリマブは,平均72%,客観的な応答率を示した.
- 完全な病理反応 (cPR) と主要な病理反応 (mPR) の高い割合が観察されました.
- 治療に関連した有害事象 (TRAE) は66%の患者で発生し,主に軽度で,疲労,発疹,下痢が最も一般的であった.
結論:
- cSCCに対する新補助剤セミプリマブは,高い応答率,低再発率,治癒可能な副作用による生存率の改善を示しています.
- この治療は免疫抑制患者でも有効であり,さらなる研究が必要である.
- 新添加剤セミプリマブはCSCCの有望で効果的な治療法ですが,長期的なデータと実用的な証拠はまだ必要です.
さらに関連する動画
関連する概念動画
Treatment Resistant Cancers
2.6K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
2.6K
Renewal of Skin Epidermal Stem Cells
2.4K
The skin is divided into epidermis, dermis, and hypodermis, the skin's outermost, middle, and inner layers. The human epidermal layer regularly undergoes renewal, where old, dead cells are replaced by new cells. Epidermal stem cells or EpiSCs divide and differentiate to restore the lost cells. For the renewal process, some EpiSCs continuously self-renew. In contrast, few others differentiate into transit-amplifying cells, which later form prickle or spinous cells, followed by granular...
2.4K
Clinical Applications of Epidermal Stem Cells
2.4K
Epidermal stem cells (EpiSCs) are mainly located at the basal layer of the epidermis. These cells repair minor injuries of the skin and replace dead skin cells. However, EpiSCs’ cannot heal severe wounds such as major burns or those from diabetes or hereditary disorders. In such cases, culturing the epidermal stem cells from the patient is possible and has yielded successful treatment options, such as laboratory-grown skin grafts. These grafts are synthesized using a patient’s own...
2.4K
Skin Diseases and Disorders
5.4K
Skin is the first line of defense and encounters a variety of microbes. Some pathogenic strains are often the cause of a broad range of infections of the skin and other body systems. These conditions can affect people of all ages and may have different causes, including genetic factors, infections, autoimmune reactions, environmental factors, and lifestyle choices.
Gram-positive Staphylococcus spp. and Streptococcus spp. are responsible for many of the most common skin infections. However, many...
Gram-positive Staphylococcus spp. and Streptococcus spp. are responsible for many of the most common skin infections. However, many...
5.4K
Skin Cancer
5.2K
Skin cancer is a type of cancer that occurs when there is an abnormal growth of skin cells, usually triggered by damage to the DNA within the skin cells. It is primarily caused by exposure to ultraviolet (UV) radiation from the sun or artificial sources like tanning beds. Skin cancer is the most common type of cancer worldwide, and its incidence continues to rise.
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
5.2K
Tumor Immunotherapy
2.5K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.5K


